valuing biotech stocks, page-3

Gungunno

This post is on the thread of your very first post on the pRR thread, and indeed your first ever post on Hotcopper, about three months ago.

At that time you asserted that you were an inexperienced biotech investor.

Ever since then you have been in the cheer squad that has sung the praises of Martin Rogers and shouted down anyone with a less sanguine view of PRR and its prospects.

Your blind confidence may yet not serve you well.

What we have is:

a) Mixed messages from PRR around the number of patients required in clinical studies for FDA approval to be received.

b) no meaningful guidance as to the cost of getting to regulatory approval.

c) very short patent life, with the result that Orphan Drug status is absolutely pivotal to their being any value in PRR.

d) misleading commentary from PRR regarding the financial strength and track record of a key investor - here I refer to Springtree being painted as an established institution when in fact it was a new entity with very low capitalisation.

Martin Rogers has done a fantastic job of breathing life into PRR. Make no mistake.

But there is a long way to go. And the extent of the challenge from here has not been clearly articulated either by the company or by anyone on this forum.

That is a fact.